Davidson Trust Co. Sells 4,252 Shares of AbbVie Inc. $ABBV

Davidson Trust Co. trimmed its stake in shares of AbbVie Inc. (NYSE:ABBV) by 12.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 29,634 shares of the company’s stock after selling 4,252 shares during the period. AbbVie accounts for 3.0% of Davidson Trust Co.’s portfolio, making the stock its 4th largest holding. Davidson Trust Co.’s holdings in AbbVie were worth $7,752,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of ABBV. Burk Holdings LLC purchased a new position in shares of AbbVie during the second quarter valued at about $30,000. Marquette Asset Management LLC lifted its position in shares of AbbVie by 52.2% in the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after buying an additional 48 shares in the last quarter. Abound Financial LLC bought a new position in AbbVie during the fourth quarter valued at approximately $32,000. Principia Wealth Advisory LLC boosted its stake in AbbVie by 38.9% during the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock valued at $40,000 after buying an additional 44 shares during the last quarter. Finally, Merkkuri Wealth Advisors LLC purchased a new position in AbbVie during the 1st quarter valued at approximately $34,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Up 1.4%

ABBV opened at $276.24 on Friday. The business has a fifty day moving average of $259.06 and a 200 day moving average of $236.63. The stock has a market cap of $488.06 billion, a P/E ratio of 78.03, a PEG ratio of 1.24 and a beta of 0.24. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $277.60.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period last year, the company earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities analysts anticipate that AbbVie Inc. will post 13.97 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.5%. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ABBV. Morgan Stanley upped their price objective on AbbVie from $296.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday. Canaccord Genuity Group upped their price target on shares of AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Cantor Fitzgerald increased their price objective on shares of AbbVie from $285.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday. Royal Bank Of Canada lifted their price objective on shares of AbbVie from $260.00 to $280.00 and gave the stock an “outperform” rating in a research note on Friday, July 10th. Finally, BNP Paribas Exane boosted their target price on shares of AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a report on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $277.18.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA breakthrough designations strengthen AbbVie’s oncology pipeline. The FDA granted two Breakthrough Therapy designations to Temab-A (telisotuzumab adizutecan) for colorectal cancer and non-small cell lung cancer. The designation can accelerate development and regulatory review, although it does not guarantee approval or commercial success. AbbVie’s Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer
• Positive Sentiment: Analysts raised their valuation targets. JPMorgan increased its target to $300 and maintained an overweight rating, while Cantor Fitzgerald lifted its target to $290 and Guggenheim reaffirmed a buy rating with a $288 target. These actions suggest analysts see additional upside from AbbVie’s growth products and pipeline. Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants
• Positive Sentiment: New products are more than offsetting Humira’s patent-loss decline. Humira revenue fell 35.9% to $756 million, but total quarterly revenue rose 10.2% to $16.99 billion. The performance indicates that immunology, neuroscience and other newer medicines are successfully replacing the former blockbuster. AbbVie Outgrew Humira’s Collapse
• Neutral Sentiment: Valuation and income appeal remain part of the debate. AbbVie’s dividend and defensive characteristics may attract income-focused investors, but the stock’s elevated valuation means continued earnings and pipeline execution are important to justify further gains. Treasury Bills or Dividend Stocks

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.06% of the stock is currently owned by company insiders.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.